38 In the index
Insulin lispro LISPRO
A fast-acting insulin (Humalog) approved for diabetes, designed to act quickly around mealtimes. Studies confirm faster blood sugar control after eating compared to older insulins, with the same core low-blood-sugar risks shared by all insulins.
Also known as Humalog
Reported dosing
Approved labelWhat has been reported in the literature and by users. This is a record of what is done, not a recommendation.
Typical dose
Individualized, dosed at mealtimes (as prescribed)
Reported range
Highly variable by patient
Route
Subcutaneous injection
Frequency
With meals, typically 3 times daily
Duration
Chronic/ongoing (as prescribed)
FDA-approved rapid-acting insulin analog (Humalog); same severe hypoglycemia risk applies to any non-medical use.
Where this comes from
FDA prescribing information
These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.